Point-of-care testing in oral anticoagulant monitoring: Implications for patient management

Disease Management and Health Outcomes

Volumn 6, Issue 5, 1999, Pages 291-301

  Sickels, Jennifer ^b   Lafata, Jennifer Elston ^b   Ansell, Jack E ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TEST; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE; HEALTH CARE COST; HOME MONITORING; HUMAN; MANAGED CARE; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PROTHROMBIN TIME; REVIEW; SELF EVALUATION; THROMBOEMBOLISM;

EID: 20644433755     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-199906050-00006     Document Type: Review

References (4)

1. Hirsh J, Dalen JE, Andersen DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S-469S
2. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996; 156: 2311-6
3. Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary care hospitals. Stroke 1997; 28: 72-6
4. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151: 1950-3